Fecal Microbiota transplantation for recurrent or refractory clostridium Difficile infection in inflammatory bowel disease

Yao Wen Cheng, Monika Fischer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Over the past decade, the incidence of Clostridium difficile infection (CDI) has more than doubled. Fecal microbiota transplant (FMT) has emerged as a guideline-based treatment for recurrent and refractory disease. However, the role of FMT for the treatment of CDI in patients with underlying inflammatory bowel disease (IBD) is controversial despite higher CDI-related complication rates in this population including mortality, colectomy, and recurrent infection. A recent multicenter study demonstrated safety and efficacy of FMT for the treatment of recurrent or refractory CDI in IBD patients with cure rates comparable to the general population, but questions still remain regarding the impact of FMT on underlying IBD and its position in the treatment paradigm.

Original languageEnglish (US)
Article number100
Pages (from-to)40-44
Number of pages5
JournalPractical Gastroenterology
Volume41
Issue number1
StatePublished - Jan 2017

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Fecal Microbiota transplantation for recurrent or refractory clostridium Difficile infection in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this